Skip to main content

Table 2 Clinical and echocardiographic findings of Group II patients (n = 63) in the two treatment groups

From: Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study

Characteristics

Placebo (n = 27)

 

Rosuvastatin (n = 36)

 

p value

 

Baseline

Followup

Baseline

Followup

 

Age, y

56 ± 12

 

59 ± 14

 

0.38

Hemodynamics

     

HR (bpm)

68 ± 8

69 ± 12

72 ± 9

71 ± 10

0.54

SBP (mm Hg)

130 ± 17

128 ± 11

130 ± 14

130 ± 15

0.81

DBP (mm Hg)

77 ± 11

74 ± 11

77 ± 11

75 ± 9

0.41

Aortic Valve Parameters

     

AVA (cm2)

1.5 ± 0.5

1.1 ± 0.3*

1.5 ± 0.4

1.1 ± 0.4†

0.58

AV peak velocity (m/s)

3.2 ± 0.1

3.9 ± 0.7*

3.2 ± 0.1

3.8 ± 0.5†

0.64

AV peak gradient (mm Hg)

41 ± 4

62 ± 23*

42 ± 4

59 ± 14†

0.35

AV mean gradient (mm Hg)

22 ± 4

35 ± 13*

23 ± 3

34 ± 9†

0.63

Left Heart Dimensions

     

IVS (mm)

11 ± 2

11 ± 2

11 ± 2

11 ± 2

0.95

PWT (mm)

10 ± 1

11 ± 2

11 ± 1

11 ± 2

0.56

LA (mm)

36 ± 6

37 ± 7

39 ± 7

39 ± 7

0.42

LVEDD (mm)

48 ± 6

47 ± 5

48 ± 6

47 ± 6

0.92

LVESD (mm)

29 ± 5

27 ± 5

28 ± 5

27 ± 6

0.36

LV mass/BSA (g/m2)

     

   Men

93 ± 22

94 ± 20

93 ± 24

96 ± 17

0.51

   Women

82 ± 17

84 ± 19

81 ± 14

83 ± 19

0.72

EF (%)

66 ± 5

66 ± 6

68 ± 6

68 ± 7

0.89

Conventional Diastolic Parameters

     

Mitral E velocity (cm/sec)

80 ± 15

81 ± 22

81 ± 22

80 ± 27

0.64

Mitral A velocity (cm/sec)

80 ± 27

78 ± 22

80 ± 27

79 ± 28

0.82

E/A ratio

1.0 ± 0.3

1.1 ± 0.2

1.0 ± 0.3

1.0 ± 0.3

0.65

Tissue Doppler Imaging

     

Lateral S'

8.1 ± 1.9

8.1 ± 1.6

8.2 ± 1.8

8.3 ± 2.2

0.72

Lateral E'

7.0 ± 1.2

6.0 ± 2.1*

7.1 ± 3.2

6.1 ± 2.6†

0.66

Lateral A'

10.1 ± 3.1

9.4 ± 3.5

10.6 ± 3.6

10.3 ± 2.3

0.55

E/E' (lateral)

11 ± 4

15 ± 3*

11 ± 3

15 ± 4†

0.62

  1. Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S', systolic annular velocity; E', early diastolic annular velocity; A', late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.